Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
EDAP TMS reported total revenues of $34.6 million for the first nine months of 2026, a significant increase from $23.8 million in the prior year period. Despite higher gross profits, the company saw an expanded operating loss of $23.8 million due to increased selling, marketing, and administrative expenses, alongside a net loss of $28.0 million for the period.
Pyxus International reported Q2 fiscal 2027 results with net income increasing to $4.1 million, despite a revenue decline to $534.4 million driven by global shipping delays and shipment timing in Asia. The company tightened its full-year Adjusted EBITDA guidance to a range of $215 million to $235 million, noting that 95% of processed inventory is already committed for the second half of the year.
Term
Q2 2027
“We closed the second quarter and first half of fiscal 2027 well-positioned to execute a heavily weighted second half. Throughout the quarter, we deployed working capital with discipline, aligning crop purchases directly with customer commitments and strengthening our position for second-half execution. Market dynamics extended purchasing timelines, while external factors including widespread global shipping delays, shifted a portion of sales into the back half of the year. Those volumes are included in our second-half shipment plan, and with nearly 95% of our lower-cost processed inventory committed, we are ready to deliver on our full-year priorities.”
Pieter Sikkel, Pyxus' President and Chief Executive Officer
Lionsgate Studios reported Q2 fiscal 2027 revenue of $668.8 million, up 41% year-over-year, driven by strong growth in Television Production and Motion Picture segments. Despite a net loss of $15.5 million, the company reported adjusted OIBDA of $72.0 million and reaffirmed confidence in its full-year growth forecast.
Term
Q2 2027
“Our strong performance in the quarter reflects all of the pieces of our fiscal 2027 plan coming together, reaffirming our confidence in this year's forecast of significant adjusted OIBDA growth.”
Jon Feltheimer, Lionsgate CEO
“We had very positive momentum in the quarter as we continued to set in place our film tentpoles for the next three years. Combined with another great library performance and continued encouraging signs in our broader operating environment, we have growing visibility into our continued growth trajectory in fiscals 2028 and 2029.”
Federal Agricultural Mortgage Corp (Farmer Mac) reported record third-quarter financial results with outstanding business volume reaching $38.5 billion, a 24% increase year-over-year. The company achieved net income attributable to common stockholders of $54.9 million ($5.03 per diluted share) and core earnings of $52.6 million, driven by strong growth in net interest income.
Term
Q3 2026
“Farmer Mac delivered record third quarter results, with outstanding business volume and year-to-date revenue and core earnings reaching new all-time highs. We achieved these results in a market environment characterized by greater uncertainty and increasingly challenging conditions. Farmer Mac’s ability to successfully navigate these market dynamics while continuing to serve as a reliable source of secondary market liquidity reflects our mission focus, the strength of our team, and our market position.”
Zachary Carpenter, President and Chief Executive Officer
“Our diversified portfolios, strong capital position, and disciplined approach to underwriting and risk management allow us to reliably support rural America through market and economic cycles. While we remain mindful of the evolving conditions in the U.S. agricultural markets and the significant investment needs to support infrastructure in rural communities, we are confident in the durability of our business model and are well positioned to continue advancing our mission while delivering high-quality earnings and long-term value for our shareholders.”
Zachary Carpenter, President and Chief Executive Officer
Tandem Diabetes Care reported Q3 2026 worldwide sales of $283.7 million, a 14% increase year-over-year, driven by strong international growth and expanded pump shipments. The company significantly narrowed its net loss to $7.1 million and reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion.
Term
Q3 2026
“Tandem’s third-quarter performance demonstrates that our strategy is delivering results. We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”
John Sheridan, president and chief executive officer
Allogene Therapeutics reported financial results for the third quarter of 2026, ending the period with $388.9 million in cash and investments. The company highlighted enrollment momentum in its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL and upcoming data presentations for its autoimmune candidate ALLO-329.
Term
Q3 2026
“We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient’s disease and closer to where they receive care.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer
“Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer
CareTrust REIT reported Q3 2026 financial results with Normalized FFO per share increasing 20% year-over-year to $0.54. The company highlighted record year-to-date investment activity of $2.9 billion, including the initial closing of a major £1.1 billion U.K. care home portfolio acquisition from LNT Care Developments.
“Normalized FFO per share increased 20% year-over-year and the team set another record of approximately $2.9 billion invested across skilled nursing, SHOP, and UK care homes, all while positioning the balance sheet for continued strong growth in the near to mid-term.”
Dave Sedgwick, Chief Executive Officer
“The CareTrust flywheel continues to accretively deliver year-over-year growth of our asset base and FFO. The relationship with LNT is a multiplier to our SHOP and UK care home growth engines. We've never been more excited for the runway ahead.”
Valley National Bancorp reported net income of $541.1 million for the nine months ended September 30, 2026, compared to $402.6 million for the same period in 2025. Total assets grew to $67.5 billion, driven by a $3.1 billion increase in net loans, while total deposits rose to $55.2 billion.
TransMedics Group reported total revenue of $203.0 million for the third quarter of 2026, a 41% increase year-over-year, driven by growth in both product and service revenue. Net income for the quarter was $17.1 million, down from $24.3 million in the prior year period, primarily due to increased operating expenses in research, development, and clinical trials.
Synaptics reported Q1 fiscal 2027 revenue of $294.0 million, a 1% increase year-over-year, despite supply constraints and smartphone market softness. The company reported a GAAP net loss of $17.7 million but achieved non-GAAP net income of $51.5 million. Due to its pending all-cash acquisition by onsemi, Synaptics did not provide forward-looking guidance.
Term
Q1 2027
“Synaptics delivered another quarter of strong design activity and customer engagement in Edge and Physical AI. We are continuing to see broader opportunities for our tactile sensing controllers and video interface products in robotics, and these new customers are showing growing interest in our processor and wireless technologies leveraging Edge AI development platforms.”
Rahul Patel, Synaptics' President and Chief Executive Officer
“Fiscal first quarter revenue was affected by supply constraints and memory-related demand dynamics across multiple markets, with smartphone softness impacting our touch and wireless products. During the quarter, we entered into a licensing agreement for our automotive LCD TDDI technology, consistent with our strategy to focus on higher-value areas and grow in Physical AI and Edge AI.”
Rahul Patel, Synaptics' President and Chief Executive Officer
Vera Therapeutics received accelerated FDA approval for its lead product, TRUTAKNA, in July 2026 and began recording limited product revenue. The company remains in a net loss position as it scales commercialization efforts and continues clinical development for other indications and product candidates.
OUTFRONT Media reported third quarter 2026 revenues of $511.1 million, a 9.3% increase year-over-year driven by strength in billboard and transit advertising. The company also declared a quarterly cash dividend of $0.33 per share and indicated expectations for double-digit revenue growth for the full year 2026.
Term
Q3 2026
“Our third quarter revenues grew over 9% given broad strength across all aspects of our business, and resulted in healthy Adjusted OIBDA and AFFO growth. We currently expect 2026 will be a double-digit revenue growth year, reflecting our focused execution and IRL’s re-emergence as an integral part of advertisers’ marketing campaigns.”
Nick Brien, Chief Executive Officer of OUTFRONT Media
Fulgent Genetics reported Q3 2026 revenue of $90.4 million, representing 8% year-over-year growth. The company reported a GAAP loss of $13.2 million and maintained its full-year 2026 revenue guidance of $330 million to $340 million. Management highlighted momentum in their therapeutics pipeline and the integration of AI into laboratory services workflows.
Term
Q3 2026
“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer
“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”
JFrog Ltd. reported third quarter 2026 revenue of $179.2 million, a 31% increase year-over-year, driven by 60% growth in cloud revenue. The company achieved a non-GAAP operating margin of 22.7% and expanded its high-value customer base, with those generating over $1 million in ARR growing 58% to 112 customers.
Term
Q3 2026
“AI agents are writing code faster than any developer can review it. Every output becomes an artifact that must be stored, secured, and governed. Speed without trust can’t scale. Enterprises are standardizing on the JFrog Platform as a system of record for their software supply chain; a control plane that gives users both, under one Platform. Our Q3 performance reflects this momentum.”
Guardant Health reported Q3 2026 revenue of $361.0 million, a 36% increase year-over-year, driven by strong performance in its Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion and highlighted the FDA approval of Guardant360 CDx as a companion diagnostic for breast cancer.
Term
Q3 2026
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”
Helmy Eltoukhy, co-founder and co-CEO
“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”
Halozyme Therapeutics reported record Q3 2026 financial results with total revenue increasing 39% year-over-year to $493 million, driven by a 44% surge in royalty revenue. Based on strong performance, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS while highlighting a legal victory in the Netherlands protecting its intellectual property against Merck.
Term
Q3 2026
“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels.”
Dr. Helen Torley, President and Chief Executive Officer
“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026.”
Darren Snellgrove, Executive Vice President and Chief Financial Officer
Fulgent Genetics reported a net loss of $13.2 million for Q3 2026 on revenue of $90.4 million, compared to a net loss of $6.6 million on $84.1 million in revenue for the same period in 2025. The company's cash and marketable securities position decreased significantly from $636.0 million at year-end 2025 to $652.3 million as of September 30, 2026, impacted by $64.6 million in common stock repurchases during the first nine months of the year.
Bentley Systems reported total revenues of $421.5 million for the third quarter of 2026, a 12.2% increase compared to the same period in 2025, driven primarily by subscription growth. Net income attributable to the company rose significantly to $89.9 million, up from $57.4 million in the prior year, reflecting improved operating margins and higher income from operations.
For the nine months ended September 30, 2026, BRC Group Holdings, Inc. reported total revenues of $624.2 million and a net loss of $3.9 million, a significant decline from the $220.0 million net income in the prior year period. The company's balance sheet shows a total deficit of $44.6 million, though this improved from a $120.3 million deficit at the end of 2025.
indie Semiconductor reported Q3 2026 revenue of $70.2 million, representing 31% year-over-year growth and exceeding the midpoint of its previous outlook. The company narrowed its non-GAAP operating loss to $7.2 million and highlighted a major radar chipset design win with a top-three North American OEM.
Term
Q3 2026
“We reported strong third quarter results, with revenue up 31 percent year-over-year, ahead of our outlook, and our non-GAAP operating loss narrowed by more than a third. Our radar chipset, in high-volume production, has been selected by one of the top three North American OEMs, our sensing and perception portfolio is expanding rapidly into Physical AI, and with our fourth quarter outlook implying approximately 33 percent year-over-year growth, indie is very well positioned for the future.”
Donald McClymont, indie’s co-founder and chief executive officer
Mustang Bio, Inc. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to $1.4 million in the prior year period. As of September 30, 2026, the company maintained $14.3 million in cash and cash equivalents and an accumulated deficit of $401.6 million, noting that additional capital will be required to fund future operations.
FIGS, Inc. reported third quarter 2026 financial results with net revenues increasing 25.7% year-over-year to $190.7 million, driven by strong growth in both scrubwear and international markets. The company achieved a net income of $19.3 million and raised its full-year 2026 revenue growth outlook to approximately 23.5%.
Term
Q3 2026
“Our momentum continued in Q3, which marked our fourth straight quarter of greater than 25% net revenues growth, powered by consistent strength across our categories, channels and geographies. This inflection in our business reflects the combined power of great product, marketing campaigns that resonate deeply, a passionate community and strong industry fundamentals.”
Trina Spear, Chief Executive Officer and Co-Founder
“We performed at a high level in Q3, delivering better-than-expected overall results. Net revenues grew 26%, highlighted by accelerations in active customer growth to 14.3%, average order value growth to 10.5%, and net revenues per active customer, which grew to a record $236.”
HA Sustainable Infrastructure Capital (HASI) reported third quarter 2026 financial results with GAAP EPS of $1.04 and Adjusted EPS of $0.82. The company's managed assets grew 27% year-over-year to $19.0 billion, and management reaffirmed its 2028 guidance for Adjusted EPS and ROE.
Term
Q3 2026
“Our team continues to execute on our business plan by adding new clients and deepening our relationships with existing ones, further diversifying into new asset classes, and optimizing our capital platform. These factors have translated into superb financial results through the first three quarters of 2026 with our Managed Assets increasing nearly $3 billion to $19 billion, Adjusted Recurring Net Investment Income growing 23% and Adjusted EPS by 15% year-to-date, and our Adjusted ROE rising to 15.6%.”
Jeffrey A. Lipson, President and Chief Executive Officer
“As much of the global economy has been adjusting to the increase in interest rates over the last few months, HASI continues to demonstrate the benefits of our business model in mitigating the impacts of a higher interest rate environment. Our new asset yields have increased to more than 11% year-to-date and we have continued to maintain our net investment margins. In combination with our growing base of management fees, we are generating greater profitability that is increasingly resilient to changes in the interest rate environment.”
For the nine months ended September 30, 2026, Sempra reported net income of $3,206 million, a significant increase from $1,588 million in 2025, driven by higher equity earnings and a gain on sales. Total revenues remained relatively stable at $9,843 million, while the company continued heavy capital investment with $7,327 million in property, plant, and equipment expenditures.
Teradata reported third quarter 2026 financial results with total revenue of $399 million and non-GAAP diluted EPS of $0.70. The company saw public cloud ARR growth of 11% year-over-year and narrowed its full-year revenue outlook to the high end of previous ranges while increasing its EPS guidance.
Term
Q3 2026
“In Q3, Teradata marked another quarter of progress against the goals we set at the start of the year, driving total ARR growth, improving profitability and delivering strong free cash flow. The increased pace of new product innovation and new AI service capabilities is driving positive interest from customers.”
For the nine months ended September 30, 2026, Sempra reported total revenues of $9,843 million and net income of $3,206 million, a significant increase from $1,588 million in the prior year. The results were impacted by a $214 million gain on sales and higher equity earnings, partially offset by $205 million in regulatory disallowances.
Sempra reported a significant increase in net income for the nine months ended September 30, 2026, reaching $3,206 million compared to $1,588 million in the prior year. This growth was driven by higher equity earnings and a gain on sales, despite a $205 million regulatory disallowance and increased interest expenses.
Simon Property Group reported Q3 2026 Real Estate FFO of $1.277 billion, or $3.37 per diluted share, representing a 4.7% increase year-over-year. The company increased its full-year 2026 Real Estate FFO guidance and raised its quarterly dividend following strong leasing momentum and shopper traffic growth.
Term
Q3 2026
“We delivered another quarter of excellent financial and operational results. Leasing momentum continued, rents and occupancy increased and shopper traffic growth accelerated for the third consecutive quarter, driving robust retailer sales growth across our portfolio. Today, we are once again increasing our full-year 2026 Real Estate FFO per share guidance and raising our quarterly dividend.”
Eli Simon, Chief Executive Officer, President and Chief Operating Officer
Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.
Akamai Technologies reported Q3 2026 revenue of $1.12 billion, up 6% year-over-year, driven by 34% growth in Cloud Infrastructure Services. The company issued bullish long-term guidance, projecting revenue growth to accelerate to 17-22% in 2027 and total revenue to exceed $7.0 billion in 2028.
Term
Q3 2026
“Akamai delivered solid third quarter results, driven by continued momentum across security and Cloud Infrastructure Services (CIS). We are especially excited by the exceptional progress in Cloud Infrastructure Services, with more than $14 billion worth of multi-year commitments signed so far this year.”
Dr. Tom Leighton, Akamai's Chief Executive Officer
“Given our CIS momentum, track record of execution and continued strong pipeline, we expect Akamai's overall revenue growth to accelerate to 17% to 22% year-over-year when adjusted for foreign exchange* in 2027. We expect further acceleration in 2028 with total revenue projected to exceed $7.0 billion.”
Dr. Tom Leighton, Akamai's Chief Executive Officer